Cardiol Therapeutics (TSX:CRDL) Inventory Turnover: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:CRDL Cardiol Therapeutics Inc TSX:CRDL
27 GF Score
Price C$2.61
! 4 Warning Signs
View Full Analysis

What is Cardiol Therapeutics Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Cardiol Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2026 was C$0.01 Mil. Cardiol Therapeutics's Average Total Inventories for the quarter that ended in Jun. 2026 was C$0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Cardiol Therapeutics's Days Inventory for the three months ended in Jun. 2026 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cardiol Therapeutics  (TSX:CRDL) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cardiol Therapeutics's Days Inventory for the three months ended in Jun. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Jun. 2026 )/Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=0/0.011546*365 / 4
=0.00

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cardiol Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Cardiol Therapeutics Inventory Turnover Related Terms

Cardiol Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Cardiol Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiol Therapeutics Inventory Turnover Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only 12.27 - - - -

Cardiol Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
TSX:CRDL
27GF Score
Cardiol Therapeutics Inc TSX:CRDL
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiol Therapeutics Inventory Turnover Calculation

Cardiol Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Inventory Turnover (A: Dec. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2025 ) / ((Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count )
=0.101983 / ((0 + 0) / 1 )
=0.101983 / 0
=N/A

Cardiol Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover (Q: Jun. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Jun. 2026 ) / ((Total Inventories (Q: Mar. 2026 ) + Total Inventories (Q: Jun. 2026 )) / count )
=0.011546 / ((0 + 0) / 1 )
=0.011546 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiol Therapeutics Business Description

Other Exchanges CRDL:USACT9:Germany
Address 2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
27GF Score

Get the complete analysis for TSX:CRDL

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$2.61
Price